GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (XMAD:GRF) » Definitions » Other Long-Term Liabilities

Grifols (XMAD:GRF) Other Long-Term Liabilities : €170 Mil (As of Dec. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Grifols Other Long-Term Liabilities?

Grifols's other long-term liabilities for the quarter that ended in Dec. 2024 was €170 Mil.

Grifols's quarterly other long-term liabilities increased from Jun. 2024 (€916 Mil) to Sep. 2024 (€9,933 Mil) but then declined from Sep. 2024 (€9,933 Mil) to Dec. 2024 (€170 Mil).

Grifols's annual other long-term liabilities declined from Dec. 2022 (€10,184 Mil) to Dec. 2023 (€165 Mil) but then increased from Dec. 2023 (€165 Mil) to Dec. 2024 (€170 Mil).

Grifols Other Long-Term Liabilities Historical Data

The historical data trend for Grifols's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Other Long-Term Liabilities Chart

Grifols Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 47.17 856.56 10,184.23 165.49 170.46

Grifols Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,171.31 165.49 915.57 9,933.01 170.46

Grifols Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Grifols Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Grifols's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Grifols Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (XMAD:GRF) » Definitions » Other Long-Term Liabilities
Comparable Companies
XMAD:ROVI XMAD:ALM XMAD:FAE XMAD:RJF XMAD:LAB LLY JNJ ABBV OCSE:NOVO B XSWX:ROG XSWX:NOVN LSE:AZN MRK AMGN PFE GILD XPAR:SAN BMY TSE:4519 LSE:GSK
Traded in Other Exchanges
GIKLY:USA GIFOF:USA GIFLF:USA GRFS:USA 1GRF:Italy GRFe:UK GRFPe:UK 0RDV:UK 0RDU:UK GRF.P:Spain G0F0:Germany G0F0:Germany OZTA:Germany OZTA:Germany G0FB:Germany GRF:Austria
Address
Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
Website
https://www.grifols.com
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.